AIGH Capital Management LLC Purchases New Stake in Protara Therapeutics, Inc. $TARA

AIGH Capital Management LLC acquired a new stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,622,733 shares of the company’s stock, valued at approximately $8,454,000. Protara Therapeutics comprises about 1.2% of AIGH Capital Management LLC’s portfolio, making the stock its 22nd biggest holding.

Several other hedge funds also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new stake in shares of Protara Therapeutics in the 2nd quarter worth about $46,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Protara Therapeutics during the second quarter worth about $53,000. Persistent Asset Partners Ltd bought a new position in shares of Protara Therapeutics during the fourth quarter worth about $57,000. AXQ Capital LP acquired a new position in Protara Therapeutics in the fourth quarter worth about $58,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Protara Therapeutics in the fourth quarter worth about $59,000. 38.13% of the stock is owned by institutional investors and hedge funds.

Protara Therapeutics Stock Performance

NASDAQ TARA opened at $4.11 on Thursday. Protara Therapeutics, Inc. has a one year low of $2.97 and a one year high of $7.82. The company has a 50-day simple moving average of $4.49 and a 200-day simple moving average of $5.28. The firm has a market capitalization of $230.98 million, a PE ratio of -3.07 and a beta of 1.48.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.05. Equities analysts forecast that Protara Therapeutics, Inc. will post -1.44 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a report on Tuesday, April 21st. Oppenheimer lifted their target price on Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 20th. HC Wainwright reiterated a “buy” rating on shares of Protara Therapeutics in a report on Wednesday, May 20th. Wall Street Zen raised Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, UBS Group reissued a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $26.25.

Protara Therapeutics Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.